For the year ending 2025-12-31, PRLD had $21,973K increase in cash & cash equivalents over the period. -$56,369K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -99,498 |
| Depreciation and amortization | 1,711 |
| Noncash lease expense | 1,534 |
| Stock-based compensation | 11,913 |
| Amortization of premium and discount on marketable securities, net | 371 |
| Prepaid expenses and other current assets | 197 |
| Accounts payable | -3,918 |
| Accrued expenses and other liabilities | -2,980 |
| Deferred revenue | 35,532 |
| Long-term prepaid expenses and other long-term assets | 0 |
| Operating lease liabilities | 28 |
| Net cash used in operating activities | -56,302 |
| Purchases of marketable securities | 100,866 |
| Proceeds from maturities of marketable securities | 154,392 |
| Purchases of property and equipment | 67 |
| Net cash provided by investing activities | 53,459 |
| Proceeds from issuance of common stock in connection with the securities purchase agreement | 24,875 |
| Payment of offering costs | 0 |
| Proceeds from issuance of common stock in connection with the exercise of stock options | 16 |
| Proceeds from the issuance of common stock under espp | 150 |
| Payment of withholding taxes related to stock-based compensation to employees | 17 |
| Principal payments on finance lease | 208 |
| Net cash provided by (used in) financing activities | 24,816 |
| Net increase (decrease) in cash and cash equivalents | 21,973 |
| Cash, cash equivalents and restricted cash at beginning of year | 16,518 |
| Cash, cash equivalents and restricted cash at end of year | 38,491 |
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)